Related Experiment Videos
[Smoking cessation program based on pharmacological support (bupropion SR). Our own experience]
Irena Porebska1, Marcin Gołecki, Kamilla Kasibowska-Kuźniar
1Katedry i Kliniki Chorób Płuc Akademii Medycznej, Wrocławiu.
Pneumonologia I Alergologia Polska
|November 1, 2003
Summary
Bupropion SR combined with an intensive smoking cessation program significantly improved abstinence rates in Polish smokers. This approach, while effective, requires careful physician supervision due to potential side effects.
Area of Science:
- Public Health
- Pharmacology
- Addiction Medicine
Context:
- Smoking remains a major preventable health risk in Poland.
- Bupropion was identified in the late 1990s for its efficacy in nicotine addiction treatment.
Purpose:
- To evaluate the effectiveness of an ambulatory, intensive smoking cessation program utilizing bupropion SR with educational support.
Summary:
- The study involved 54 smokers (mean age 45.5 years) who smoked 10-50 cigarettes daily.
- An early abstinence rate of 61.1% was observed at 7 weeks, with 45.2% remaining non-smokers at 6 months.
- Common side effects included dry mouth and sleep disturbances; 13% discontinued bupropion due to adverse effects.
Impact:
- High abstinence rates suggest intensive programs are valuable components of anti-nicotine strategies.
- Pharmacological support for nicotine dependence necessitates close medical supervision.